858 related articles for article (PubMed ID: 19581537)
1. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
[TBL] [Abstract][Full Text] [Related]
4. [Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].
Xie DR; Liang HL; Yang Q; Guo SS; Jiang ZM
Ai Zheng; 2007 Aug; 26(8):895-9. PubMed ID: 17697555
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
Li J; Merl M; Lee MX; Kaley K; Saif MW
Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Cunningham D; Chau I; Stocken DD; Valle JW; Smith D; Steward W; Harper PG; Dunn J; Tudur-Smith C; West J; Falk S; Crellin A; Adab F; Thompson J; Leonard P; Ostrowski J; Eatock M; Scheithauer W; Herrmann R; Neoptolemos JP
J Clin Oncol; 2009 Nov; 27(33):5513-8. PubMed ID: 19858379
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.
Heinemann V; Boeck S; Hinke A; Labianca R; Louvet C
BMC Cancer; 2008 Mar; 8():82. PubMed ID: 18373843
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study.
Demols A; Peeters M; Polus M; Marechal R; Gay F; Monsaert E; Hendlisz A; Van Laethem JL
Br J Cancer; 2006 Feb; 94(4):481-5. PubMed ID: 16434988
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
Tempero M; Plunkett W; Ruiz Van Haperen V; Hainsworth J; Hochster H; Lenzi R; Abbruzzese J
J Clin Oncol; 2003 Sep; 21(18):3402-8. PubMed ID: 12885837
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.
Louvet C; André T; Lledo G; Hammel P; Bleiberg H; Bouleuc C; Gamelin E; Flesch M; Cvitkovic E; de Gramont A
J Clin Oncol; 2002 Mar; 20(6):1512-8. PubMed ID: 11896099
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
[TBL] [Abstract][Full Text] [Related]
17. Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Schlick K; Gantschnigg A; Seymer A; Huemer F; Greil R; Weiss L
Cancer Med; 2023 Aug; 12(16):16997-17004. PubMed ID: 37537780
[TBL] [Abstract][Full Text] [Related]
18. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
[TBL] [Abstract][Full Text] [Related]
19. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.
Moureau-Zabotto L; Phélip JM; Afchain P; Mineur L; André T; Vendrely V; Lledo G; Dupuis O; Huguet F; Touboul E; Balosso J; Louvet C
J Clin Oncol; 2008 Mar; 26(7):1080-5. PubMed ID: 18309942
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
Heinemann V; Quietzsch D; Gieseler F; Gonnermann M; Schönekäs H; Rost A; Neuhaus H; Haag C; Clemens M; Heinrich B; Vehling-Kaiser U; Fuchs M; Fleckenstein D; Gesierich W; Uthgenannt D; Einsele H; Holstege A; Hinke A; Schalhorn A; Wilkowski R
J Clin Oncol; 2006 Aug; 24(24):3946-52. PubMed ID: 16921047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
